CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Memantinedrug
Likely dose
Memantine 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01038128
NCT01038128N/ACompleted
CompareCT.gov

Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder: An Open-Label Trial of Memantine

Mclean Hospital·interventional·Posted Dec 23, 2009·Updated May 4, 2015

In Brief

A clinical study evaluating Memantine for Bulimia Nervosa and Body Dysmorphic Disorder. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The primary objective of this 13-week clinical trial is to test the hypothesis that treatment with Memantine will significantly improve the symptoms of those suffering from either bulimia nervosa, purging type or suffering from body dysmorphic disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBulimia Nervosa, Body Dysmorphic Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 23, 2009
Enrollment StartDec 1, 2009
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.5 years ago

Interventions

Memantinedrug

Drug: Memantine, 10-40 mg daily